Could a gene test predict your best asthma treatment?
NCT ID NCT03694158
Summary
This study aims to see if people with a specific gene variant (IL-4RαR576) respond better to the asthma drug dupilumab. About 150 participants, ages 12 and older with moderate-to-severe asthma, will receive either the drug or a placebo for 48 weeks. The main goal is to see if the drug reduces the rate of serious asthma attacks, especially for those with the gene variant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
MetroHealth System
Cleveland, Ohio, 44109, United States
-
Montefiore Einstein Clinical Research Center
The Bronx, New York, 10467, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.